Observe
Identify clinically meaningful features in imaging and pathology.
Loading
AI and multimodal intelligence for oncology
Revealing clinically meaningful signals hidden in cancer data.
Existential Intelligence combines radiological imaging, digital pathology, machine learning, and specialized clinical expertise to develop prognostic insights for clinical trials, drug development, diagnostics, and patient care.
Radiology
Pathology
Clinical data
Separate modalities. One clinically meaningful picture.
Our thesis
Cancer data is often analyzed in fragments. Its greatest value may exist in the relationships between them.
Radiology, pathology, biomarkers, and clinical outcomes are commonly evaluated through separate workflows. Existential Intelligence develops models and analytical methods that connect these sources to identify patterns associated with disease progression, treatment response, prognosis, and clinical-trial outcomes.
Connect
Relate those features to biological, treatment, and outcome data.
Translate
Develop validated insights, partner programs, and commercial products.
Prognostic signal
Our scientific advantage
Specialized clinical knowledge is the foundation of useful oncology AI.
Our initial focus is macrovascular invasion in pancreatic ductal adenocarcinoma and other cancers with high vascular proximity. This work brings together expertise in radiology, pathology, oncology, biomedical informatics, machine learning, and secure software development.
A clinically important beachhead
Macrovascular invasion may influence prognosis, treatment response, patient stratification, and the interpretation of clinical-trial outcomes.
A multidisciplinary expert network
Our coalition includes specialists with access to clinical collaborators, patient populations, imaging, pathology, and pancreatic cancer expertise across multiple institutions and regions.
A platform built to expand
The same combination of scientific expertise, multimodal data, and computational methods can support additional cancer indications, biomarkers, and commercial applications.
PhaseVantage applies this expertise to clinical-development decisions in pancreatic cancer. Visit PhaseVantage →
Founding team
Clinical science, computational intelligence, and secure product development.
Our founders bring together expertise in pancreatic cancer, radiology and pathology-informed research, biomedical informatics, computational biology, artificial intelligence, software engineering, and cybersecurity.
Dr. Kirk Gasper, Ph.D.
CEO, informatics lead, co-founder
Biomedical informatics scientist focused on cancer biology, pancreatic cancer progression, and clinically meaningful patient outcomes.
View full bio →
Dr. Matteo Ligorio, M.D.
Surgical lead, macrovascular invasion lead, co-founder
Physician-scientist specializing in pancreatic cancer biology, clinical research, translational oncology, and macrovascular invasion.
View full bio →
Dr. Dario Ghersi, M.D., Ph.D.
Computational biology and AI lead, co-founder
Biomedical informatics and computational biology expert whose work spans cancer genomics, immunoinformatics, structural bioinformatics, and machine intelligence.
View full bio →
Dr. Matt Hale, Ph.D.
Enterprise software architect, cybersecurity lead, co-founder
Cybersecurity and software-engineering researcher focused on building secure, scalable, and human-centered technology systems.
View full bio →Commercial roadmap
One scientific platform. Multiple paths to commercial value.
Existential Intelligence is developing a portfolio of opportunities around imaging-derived biomarkers, digital pathology, prognostic modeling, clinical-development intelligence, and longitudinal treatment assessment.
1. Validate specialized insights
Retrospective studies, cohort analysis, model development, and external validation.
2. Develop with strategic partners
Milestone-based programs with pharmaceutical, diagnostic, clinical, and data partners.
3. Translate into commercial offerings
Clinical-trial services, licensed models, diagnostic products, decision-support tools, royalties, and product-specific revenue sharing.
Clinical-trial intelligenceImaging-derived biomarkersH&E digital pathologyPrognostic modelsTreatment-effect assessmentAdditional cancer indications
What Existential Intelligence brings
- Specialized expertise in macrovascular invasion and cancers with high vascular proximity
- Radiological imaging and digital pathology capabilities
- Machine-learning and multimodal modeling expertise
- Clinical and scientific collaborators across multiple institutions and regions
- Secure software engineering and analytical infrastructure
- Proprietary methods, workflows, and technical knowledge
What strategic partners can provide
- Clinical data and specimens
- Prospective or external validation settings
- Diagnostic and laboratory infrastructure
- Drug-development programs
- Regulatory and reimbursement experience
- Commercial distribution
- Market access
- Strategic capital
Start a conversation